Your browser doesn't support javascript.
loading
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
Geerlinks, Ashley V; Scull, Brooks; Krupski, Christa; Fleischmann, Ryan; Pulsipher, Michael A; Eapen, Mary; Connelly, James A; Bollard, Catherine M; Pai, Sung-Yun; Duncan, Christine N; Kean, Leslie S; Baker, K Scott; Burroughs, Lauri M; Andolina, Jeffrey R; Shenoy, Shalini; Roehrs, Philip; Hanna, Rabi; Talano, Julie-An; Schultz, Kirk R; Stenger, Elizabeth O; Lin, Howard; Zoref-Lorenz, Adi; McClain, Kenneth L; Jordan, Michael B; Man, Tsz-Kwong; Allen, Carl E; Marsh, Rebecca A.
Afiliación
  • Geerlinks AV; Division Hematology and Oncology, Children's Hospital at London Health Sciences Centre, Western University, London, ON, Canada.
  • Scull B; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Krupski C; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Fleischmann R; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
  • Pulsipher MA; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Eapen M; Division of Hematology and Oncology, Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT.
  • Connelly JA; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Bollard CM; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
  • Pai SY; Center for Cancer and Immunology Research, Children's National Hospital and The George Washington University, Washington, DC.
  • Duncan CN; National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD.
  • Kean LS; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA.
  • Baker KS; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA.
  • Burroughs LM; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA.
  • Andolina JR; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA.
  • Shenoy S; Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY.
  • Roehrs P; Division of Pediatric Hematology-Oncology, Washington University School of Medicine, St. Louis, MO.
  • Hanna R; Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA.
  • Talano JA; Department of Pediatric Hematology and Oncology and BMT, Cleveland Clinic, Cleveland, OH.
  • Schultz KR; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
  • Stenger EO; Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
  • Lin H; Aflac Center and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA.
  • Zoref-Lorenz A; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.
  • McClain KL; Hematology Institute, Meir Medical Center, Kfar Saba, Israel.
  • Jordan MB; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Man TK; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Allen CE; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Marsh RA; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.
Blood Adv ; 7(14): 3725-3734, 2023 07 25.
Article en En | MEDLINE | ID: mdl-37042921
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Canadá